On Monday, TransCanada Corporation (USA)(NYSE:TRP)’s shares declined -0.03% to $34.54.
TransCanada’s Prince Rupert Gas Transmission Project and Coastal GasLink Pipeline Project are happy to declare a $250,000 partnership with the Tribal Resources Investment Corporation (TRICORP) to offer skills development and training for Aboriginal people in northwestern B.C. through TransCanada’s Pathway to Pipeline Readiness program. Since August of 2014, TransCanada (TRP) (TRP) has spent over $1 million on skills training initiatives in northern B.C., supporting local colleges and Aboriginal training organizations.
TRICORP is the Service Canada delivery agent in the Northwest B.C. region for the Aboriginal Skills and Employment Training Strategy (ASETS). The organization’s mission statement is “Our Vision for Our People; Economic Self Reliance”. TRICORP’s programs and services are targeted to entrepreneurs to start or expand their business, in addition to enhance capacity to deliver quality employment programming that offers skills development and training initiatives to Aboriginal citizens living in northwestern B.C.
Coastal GasLink is proposing to construct and operate (subject to required regulatory and commercial approvals) a 670-kilometre natural gas pipeline from the Groundbirch area near Dawson Creek, B.C. to the projected LNG Canada liquefied natural gas export facility near Kitimat, B.C. Project details can be found at www.coastalgaslink.com.
TransCanada Corporation operates as an energy infrastructure company in North America. The company operates in three segments: Natural Gas Pipelines, Liquids Pipelines, and Energy. The Natural Gas Pipelines segment owns and operates natural gas pipelines and regulated natural gas storage facilities.
Regeneron Pharmaceuticals Inc(NASDAQ:REGN)’s shares dropped -3.81% to $529.38.
Regeneron Pharmaceuticals, Inc. (REGN) declared a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) to develop, test and manufacture a monoclonal antibody therapy for the treatment of Ebola virus infection.
HHS will provide initial funding of about $17 million to support preclinical development and antibody manufacturing. This initial funding is designed to support an Investigational New Drug application with the U.S. Food and Drug Administration (FDA). Options in the agreement provide for an additional $21 million for a Phase 1 study in healthy volunteers, which is planned for January 2016, and further manufacturing and development studies.
Regeneron utilized its proprietary VelociGene® and VelocImmune® technologies, which enable the rapid identification and preclinical validation of fully human monoclonal antibodies, to develop a novel antibody therapy “cocktail” which comprises a mixture of three antibodies. These technologies enabled the rapid identification and scale-up of the investigational antibody therapy. To date, Regeneron has conducted pre-clinical studies in animal models of Ebola virus infection. These antibodies have been discovered and developed following Regeneron’s 2009 antibody discovery and development agreement with Sanofi and are subject to Sanofi’s opt-in rights for development and commercialization.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products comprise EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children.
At the end of Monday’s trade, Extreme Netoperates, Inc(NASDAQ:EXTR)‘s shares surged 0.44% to $3.41.
Extreme Netoperates, Inc. (EXTR) declared it has been positioned the furthest by Gartner, Inc. in the “Visionaries” quadrant of the September 2015 Magic Quadrant for Wired and Wireless LAN Access Infrastructure for “Completeness of Vision.”
According to Gartner, “a vendor in the Visionaries quadrant demonstrates an ability to enhance features in its offering to provide a unique and differentiated approach to the market. Visionaries will have innovated in one or more of the key areas of access layer technologies within the enterprise (for example, convergence, security, administration or operational efficiency). The ability to apply differentiating functionality across the entire access layer will affect their position.”
Extreme Netoperates, Inc., together with its auxiliaries, provides wired and wireless network infrastructure equipment, software, and services for enterprises, data centers, and service providers.
Newpark Resources Inc(NYSE:NR), ended its Monday’s trading session with -0.52% loss, and closed at $5.71.
Newpark Resources, Inc. (NR) declared that administration will take part in three investor conferences in September, counting the Credit Suisse Annual Small & Mid Cap Conference on September 17th; the Cowen and Company Houston Oilfield One-on-One Day on September 23rd; and the Johnson Rice Energy Conference on September 28th.
ULTRA-DEEPWATER FLUIDS CONTRACT AWARD
The Company declared that it has been awarded a contract by Total S.A. to provide drilling fluids and related services for an exploratory ultra-deepwater well in Block 14 of offshore Uruguay. This project is predictable to start in the second quarter of 2016 and generate about $10 million of revenue.
Newpark Resources, Inc. provides various products and services primarily to the oil and gas exploration industry. The company operates in two segments, Fluids Systems, and Mats and Integrated Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
